JP2010506146A - 心不全を伴う気道および肺の感染または炎症性疾患の診断 - Google Patents
心不全を伴う気道および肺の感染または炎症性疾患の診断 Download PDFInfo
- Publication number
- JP2010506146A JP2010506146A JP2009529533A JP2009529533A JP2010506146A JP 2010506146 A JP2010506146 A JP 2010506146A JP 2009529533 A JP2009529533 A JP 2009529533A JP 2009529533 A JP2009529533 A JP 2009529533A JP 2010506146 A JP2010506146 A JP 2010506146A
- Authority
- JP
- Japan
- Prior art keywords
- marker
- heart failure
- diagnosis
- determination
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 44
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 22
- 238000003745 diagnosis Methods 0.000 title claims description 35
- 208000015181 infectious disease Diseases 0.000 title claims description 13
- 230000002685 pulmonary effect Effects 0.000 title description 6
- 230000000241 respiratory effect Effects 0.000 title description 5
- 108010048233 Procalcitonin Proteins 0.000 claims abstract description 45
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 43
- 239000003550 marker Substances 0.000 claims abstract description 25
- 208000032376 Lung infection Diseases 0.000 claims abstract description 15
- 206010035664 Pneumonia Diseases 0.000 claims description 43
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 13
- 102100032752 C-reactive protein Human genes 0.000 claims description 13
- 102100034296 Natriuretic peptides A Human genes 0.000 claims description 8
- 206010006451 bronchitis Diseases 0.000 claims description 8
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- -1 NT-proANP Proteins 0.000 claims description 5
- 102400001263 NT-proBNP Human genes 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 101710187800 Natriuretic peptides A Proteins 0.000 claims description 4
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 4
- 101710187802 Natriuretic peptides B Proteins 0.000 claims description 4
- 102000004903 Troponin Human genes 0.000 claims description 4
- 108090001027 Troponin Proteins 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000001452 natriuretic effect Effects 0.000 claims description 4
- 230000002644 neurohormonal effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- 108010012004 proadrenomedullin Proteins 0.000 claims description 3
- 102000034567 proadrenomedullin Human genes 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 101800000285 Big gastrin Proteins 0.000 claims description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 2
- 108010092277 Leptin Proteins 0.000 claims description 2
- 102000016267 Leptin Human genes 0.000 claims description 2
- 102000036675 Myoglobin Human genes 0.000 claims description 2
- 108010062374 Myoglobin Proteins 0.000 claims description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 claims description 2
- 102100028427 Pro-neuropeptide Y Human genes 0.000 claims description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 238000003748 differential diagnosis Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229940039781 leptin Drugs 0.000 claims description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 claims description 2
- 108010072272 proendothelin 1 Proteins 0.000 claims description 2
- 108010088603 proneuropeptide Y Proteins 0.000 claims description 2
- 108010001670 prosomatostatin Proteins 0.000 claims description 2
- GGYTXJNZMFRSLX-UHFFFAOYSA-N prosomatostatin Chemical compound C1CCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NCC(=O)NC2C(NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(C(=O)NC(CO)C(=O)NC(CSSC2)C(O)=O)C(C)O)C(C)O)=O)N1C(=O)C(C)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(N)CO GGYTXJNZMFRSLX-UHFFFAOYSA-N 0.000 claims description 2
- 208000005333 pulmonary edema Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 claims 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 206010013975 Dyspnoeas Diseases 0.000 description 10
- 208000000059 Dyspnea Diseases 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010071436 Systolic dysfunction Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000605788 Masaia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000024796 pleuritic chest pain Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
最初の検査の間に、呼吸困難の主症状で病院の救急治療室に来院した患者の血液サンプルを採取した。遠心によって得たEDTA血漿を、アリコートに分け、そしてPCTの測定を行うまで−80℃で保存した。PCTをアッセイB・R・A・H・M・S PCT感受性LIA(BRAHMS AG、Hennigsdorf、Germany)を用いて測定した(Morgenthaler NG、Struck J、Fischer−Schulz C、Bergmann A、Sensitive Immunoluminometric Assay for the Detection of Procalcitonin、Clin Chem 48(2002)、788−790頁)。そのアッセイは、0.01ng/mLの分析的アッセイ感度を有する。
Claims (21)
- 心不全を伴う気道および肺の感染または炎症性疾患の診断のための方法であって、マーカーであるプロカルシトニンまたはその部分的な配列の決定が、検査される患者において行われることを特徴とする、方法。
- インビトロ診断であることを特徴とする、請求項1に記載の方法。
- 前記プロカルシトニンの前記決定が、0.01ng/mLから1ng/mLの範囲において、0.03ng/mLから0.06ng/mLの閾値を実証する、請求項1または2に記載の方法。
- 前記マーカーであるプロカルシトニンが、アミノ酸1−116および/またはアミノ酸3−116からなる、請求項1または2に記載の方法。
- 前記気道または肺の感染が、細菌、ウイルス、真菌、または寄生虫によって引き起こされ、そして気管支炎、特に腐敗性気管支炎、肺炎、サルコイドーシス、気管支拡張症、非心臓性肺浮腫からなる群より選択される、前述の請求項のいずれか1項に記載の方法。
- 前記気道または肺の炎症性疾患は、間質性肺疾患および肺線維症、慢性閉塞性肺疾患(COPD)、特にCOPD感染増悪、気管支喘息、特に気管支喘息の場合の感染増悪、気管支癌腫からなる群より選択される、前述の請求項のいずれか1項に記載の方法。
- さらに、炎症性マーカー、心血管マーカー、神経ホルモンマーカー、または虚血マーカーからなる群より選択される少なくとも1つの他のマーカーの決定が、検査する患者において行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記炎症性マーカーが、C−反応性タンパク質(CRP)、例えばTNF−アルファのようなサイトカイン、例えばIL−6のようなインターロイキン、およびVCAMまたはICAMのような接着分子、GDF−15またはST2の群の少なくとも1つのマーカーから選択されることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 心血管マーカーが、クレアチンキナーゼ、ミオグロビン、ナトリウム利尿タンパク質、特にANP(またはANF)、proANP、NT−proANP、BNP、proBNP、NT−proBNP、または各例におけるそれらの部分的配列、心筋トロポニン、CRP、ならびに、特にプロ−ガストリン放出ペプチド(proGRP)、プロ−エンドセリン−1、プロ−レプチン、プロ−ニューロペプチド−Y、プロ−ソマトスタチン、プロ−ニューロペプチド−YY、プロ−オピオメラノコルチン、またはプロ−アドレノメデュリン(proADM)、または各例におけるそれらの部分的配列のような、循環調節(プロ)ホルモンの群の少なくとも1つのマーカーから選択されることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記虚血マーカーが、トロポニンIおよびT、CK−MBの群からの少なくとも1つのマーカーから選択されることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記神経ホルモンマーカーが、少なくとも1つのナトリウム利尿タンパク質、特にANP(またはANF)、proANP、NT−proANP、BNP、proBNP、NT−proBNP、またはそれらの部分的配列であることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記マーカーの平行または同時決定が行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記決定が、少なくとも1つの患者サンプルに対して行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記決定が、自動化分析装置を用いて、特にKryptorによって行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記決定が、迅速なテストにより、特に単一パラメーターまたは複数パラメーターの決定を用いて行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記決定が、リスクに従って患者を分類するために行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記診断が、臨床的な決定のため、特に心不全の処置または治療のため、そして気道および肺の感染/炎症性疾患の処置または治療のための薬剤によるさらなる処置のため、ならびに抗生物質の治療コントロールのため、そして/または特に集中治療医療または救急医療において、リスクに従って患者を分類するために行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 前記診断が、予防のために、早期の認識および鑑別診断による認識のために、重症度の程度の評価のために、そして治療の過程を通して、心不全を伴う気道および肺の感染または炎症性疾患の進展の評価のために、行われることを特徴とする、前述の請求項のいずれか1項に記載の方法。
- 心不全を伴う気道および肺の感染または炎症性疾患の診断のための、プロカルシトニンまたはその部分的配列、および必要に応じて請求項7〜11のいずれか1項に記載の他のマーカーの、使用。
- 請求項1〜18のいずれか1項に記載の方法を行うための、診断装置。
- 心不全を伴う気道および肺の感染または炎症性疾患の診断またはリスク分類のためのキットであって、そのマーカーであるプロカルシトニンまたはその部分配列および必要に応じて請求項7〜11のいずれか1項に記載の他のマーカーと、付属品とを含む、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006046996A DE102006046996A1 (de) | 2006-10-01 | 2006-10-01 | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
DE102006046996.8 | 2006-10-01 | ||
PCT/DE2007/001759 WO2008040328A2 (de) | 2006-10-01 | 2007-10-01 | Diagnose von infektionen oder entzündungserkrankungen der atemwege und lunge assoziiert mit herzinsuffizienz |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012148614A Division JP5663531B2 (ja) | 2006-10-01 | 2012-07-02 | 心不全を伴う気道および肺の感染または炎症性疾患の診断 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010506146A true JP2010506146A (ja) | 2010-02-25 |
JP5058263B2 JP5058263B2 (ja) | 2012-10-24 |
Family
ID=39134486
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009529533A Active JP5058263B2 (ja) | 2006-10-01 | 2007-10-01 | 心不全を伴う気道および肺の感染または炎症性疾患の診断 |
JP2012148614A Active JP5663531B2 (ja) | 2006-10-01 | 2012-07-02 | 心不全を伴う気道および肺の感染または炎症性疾患の診断 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012148614A Active JP5663531B2 (ja) | 2006-10-01 | 2012-07-02 | 心不全を伴う気道および肺の感染または炎症性疾患の診断 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8465941B2 (ja) |
EP (1) | EP2084545B1 (ja) |
JP (2) | JP5058263B2 (ja) |
CN (1) | CN101553733B (ja) |
DE (1) | DE102006046996A1 (ja) |
ES (1) | ES2455168T3 (ja) |
HK (1) | HK1137807A1 (ja) |
WO (1) | WO2008040328A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010526305A (ja) * | 2007-05-08 | 2010-07-29 | ブラームズ アクチェンゲゼルシャフト | Nt−プロet−1を用いる診断およびリスク層別化 |
JP2011526684A (ja) * | 2008-07-02 | 2011-10-13 | アポサイエンス アクチエンゲゼルシャフト | Copd診断 |
JP2015089364A (ja) * | 2013-11-07 | 2015-05-11 | 有限会社ジェノテックス | 体細胞多重変異によるがん診断方法、がん医薬開発方法及びがん診断装置 |
JP2015515630A (ja) * | 2012-04-12 | 2015-05-28 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
WO2022176287A1 (ja) * | 2021-02-18 | 2022-08-25 | 国立大学法人大阪大学 | 評価装置、評価システム、評価方法、評価プログラムおよび記録媒体 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1882945A1 (en) * | 2006-07-28 | 2008-01-30 | F.Hoffmann-La Roche Ag | Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath |
DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
DE602008021800C5 (de) * | 2007-08-03 | 2022-05-05 | B.R.A.H.M.S Gmbh | Antibiotikum zur Behandlung von lokaler Infektion |
EP2318844A1 (en) * | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
PT2419741T (pt) | 2009-04-14 | 2019-11-04 | Brahms Gmbh | Avaliação de risco para tratamento com antibióticos em pacientes que sofrem de doença não infeciosa primária através da determinação do nível de procalcitonina |
CN102449486B (zh) * | 2009-06-05 | 2015-01-21 | B.R.A.H.M.S有限公司 | 在患有呼吸困难的对象中检测细菌感染 |
WO2011023813A1 (en) | 2009-08-28 | 2011-03-03 | Brahms Gmbh | Procalcitonin for the prognosis of adverse events |
RU2618437C2 (ru) * | 2010-11-01 | 2017-05-03 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
EP3438668A1 (en) * | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
WO2021204984A1 (en) | 2020-04-09 | 2021-10-14 | B.R.A.H.M.S Gmbh | Biomarkers for the diagnosis of respiratory tract infections |
US11287396B2 (en) | 2020-06-05 | 2022-03-29 | Princeton Biochemicals, Inc. | Method and system for simultaneous determination of multiple measurable biomarkers during the development of a communicable disease |
EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
ES2280170T3 (es) | 1999-12-22 | 2007-09-16 | Dade Behring Marburg Gmbh | Soluciones de procalcitonina humana. |
DE10027954A1 (de) | 1999-12-22 | 2001-06-28 | Dade Behring Marburg Gmbh | Humanes Procalcitonin, dessen Herstellung und Verwendung |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
-
2006
- 2006-10-01 DE DE102006046996A patent/DE102006046996A1/de not_active Ceased
-
2007
- 2007-10-01 US US12/443,897 patent/US8465941B2/en active Active
- 2007-10-01 ES ES07817601.3T patent/ES2455168T3/es active Active
- 2007-10-01 JP JP2009529533A patent/JP5058263B2/ja active Active
- 2007-10-01 EP EP07817601.3A patent/EP2084545B1/de active Active
- 2007-10-01 CN CN200780036753.6A patent/CN101553733B/zh active Active
- 2007-10-01 WO PCT/DE2007/001759 patent/WO2008040328A2/de active Application Filing
-
2010
- 2010-02-05 HK HK10101319.0A patent/HK1137807A1/xx unknown
-
2012
- 2012-07-02 JP JP2012148614A patent/JP5663531B2/ja active Active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010526305A (ja) * | 2007-05-08 | 2010-07-29 | ブラームズ アクチェンゲゼルシャフト | Nt−プロet−1を用いる診断およびリスク層別化 |
JP2011526684A (ja) * | 2008-07-02 | 2011-10-13 | アポサイエンス アクチエンゲゼルシャフト | Copd診断 |
JP2015515630A (ja) * | 2012-04-12 | 2015-05-28 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
JP2015089364A (ja) * | 2013-11-07 | 2015-05-11 | 有限会社ジェノテックス | 体細胞多重変異によるがん診断方法、がん医薬開発方法及びがん診断装置 |
WO2022176287A1 (ja) * | 2021-02-18 | 2022-08-25 | 国立大学法人大阪大学 | 評価装置、評価システム、評価方法、評価プログラムおよび記録媒体 |
Also Published As
Publication number | Publication date |
---|---|
WO2008040328A2 (de) | 2008-04-10 |
JP5663531B2 (ja) | 2015-02-04 |
EP2084545A2 (de) | 2009-08-05 |
US8465941B2 (en) | 2013-06-18 |
CN101553733A (zh) | 2009-10-07 |
US20100047835A1 (en) | 2010-02-25 |
ES2455168T3 (es) | 2014-04-14 |
JP5058263B2 (ja) | 2012-10-24 |
HK1137807A1 (en) | 2010-08-06 |
JP2012185187A (ja) | 2012-09-27 |
CN101553733B (zh) | 2014-02-26 |
EP2084545B1 (de) | 2014-02-12 |
WO2008040328A3 (de) | 2008-06-05 |
DE102006046996A1 (de) | 2008-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5663531B2 (ja) | 心不全を伴う気道および肺の感染または炎症性疾患の診断 | |
US11241395B2 (en) | Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease | |
JP4828600B2 (ja) | 心疾患の診断のためのnt−プロanpおよびnt−プロbnpの使用 | |
CN101932940B (zh) | 稳定性冠状动脉疾病中的风险分级方法 | |
JP6170101B2 (ja) | プロバソプレシン、特にコペプチンもしくはニューロフィジンiiによる、気道および肺の感染および慢性疾患の診断および/または危険性の層化 | |
CN102449486B (zh) | 在患有呼吸困难的对象中检测细菌感染 | |
ES2455191T3 (es) | Procedimiento para determinar la parte de la región media de proANP amino-terminal en pacientes que presentan una cardiopatía o que se sospecha que desarrollan o que presentan una cardiopatía | |
JP5190067B2 (ja) | Nt−プロbnpと組み合わせてのct−プロet−1による急性冠症候群の診断および危険性の分類 | |
US20100261284A1 (en) | Using gdf 15 to assess patients presenting to emergency units | |
WO2009100907A1 (en) | Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers | |
JP6474730B2 (ja) | sCD14−STの、心血管疾患若しくは状態又はアテローム性動脈硬化症のマーカーとしての使用 | |
JP2010503837A (ja) | 冠動脈カテーテル法に起因する心臓合併症の診断のためのナトリウム利尿ペプチド | |
Piechota et al. | N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients | |
JP2012516436A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110816 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120328 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120423 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120501 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120530 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120702 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120726 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120731 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150810 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5058263 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |